Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure.

about

Complex relationships between co-morbidity, outcomes, and treatment effect in heart failure.

P2860

Q50118002-C8CEEE2D-AF58-4DDE-9515-16270C7525C7

P2860

Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure.

Item

http://www.wikidata.org/entity/Q47386435

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Contribution of cardiac and ex ...... ion fraction in heart failure.

@en

Contribution of cardiac and ex ...... ion fraction in heart failure.

@nl

type

Item

label

Contribution of cardiac and ex ...... ion fraction in heart failure.

@en

Contribution of cardiac and ex ...... ion fraction in heart failure.

@nl

prefLabel

Contribution of cardiac and ex ...... ion fraction in heart failure.

@en

Contribution of cardiac and ex ...... ion fraction in heart failure.

@nl

P1476

Contribution of cardiac and ex ...... ion fraction in heart failure.

@en

P2093

Brian Claggett

http://www.w3.org/2001/XMLSchema#string

Emil Wolsk

http://www.w3.org/2001/XMLSchema#string

John J V McMurray

http://www.w3.org/2001/XMLSchema#string

Marc A Pfeffer

http://www.w3.org/2001/XMLSchema#string

Scott D Solomon

http://www.w3.org/2001/XMLSchema#string

Stuart Pocock

http://www.w3.org/2001/XMLSchema#string

P2860

What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?

Angiotensin-neprilysin inhibition versus enalapril in heart failure

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Fail

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.

Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies.

Spironolactone for heart failure with preserved ejection fraction.

P31

scholarly article

P356

10.1002/EJHF.1073

http://www.w3.org/2001/XMLSchema#string

P50

Salim Yusuf

Lars Køber

Christopher B. Granger

Karl Swedberg

P577

2017-11-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29193462

http://www.w3.org/2001/XMLSchema#string

Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure.

about

P2860

P2860

Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P31

P356

P50

P577

P698